Insights
Benchmark International Successfully Facilitated the Transaction Between Triducive Partners Ltd and Bioscript Group Limited
May 26, 2026
Benchmark International is pleased to announce the transaction between Triducive and Bioscript.
Founded in 2009 and based in St Albans, Hertfordshire, Triducive works with many of the world's leading pharmaceutical companies, including AstraZeneca and Johnson & Johnson. Co-founders Tim Warren and Nick Williams will remain with the business, ensuring continuity for clients as Triducive integrates into Bioscript's Data and Insights division.
Bioscript is a specialist healthcare communications and scientific services group backed by Sovereign Capital Partners.
Triducive is the fifth acquisition completed by Bioscript since Sovereign invested in the business in 2021. The addition further strengthens Bioscript's ability to support clients across the full medical affairs value chain, from evidence generation through to publication, advisory boards, and scientific communications.
Schedule a confidential consultation.
Tim Warren, managing partner of Triducive, said: "Joining Bioscript Group gives us the platform to broaden the impact of our work. The ability to pair our insight generation with Bioscript’s communications expertise will enable clients to translate evidence into action more effectively and with greater reach. The alignment of values and ambition makes this an exciting partnership for our team and our clients."
Gabrielle Silver, CEO at Bioscript, said: "Triducive brings exceptional strength in generating the kind of structured, practice‑based insights that help clients understand what truly influences clinical and policy decision‑making. By combining this with Bioscript’s strategic communications expertise, we can support clients with programmes grounded in real world experience."
Dominic Dalli, managing partner at Sovereign, said: "Triducive is a high-quality addition that meaningfully strengthens Bioscript's proposition. Their expertise in distilling expert clinical consensus sits at the upstream end of the medical affairs value chain, and combining it with Bioscript's communications platform creates a compelling, integrated offering for clients."
Share This Post
Categories
Get These Insights Delivered Directly To Your Email
Explore our curated collection today and stay ahead of the curve in M&A.
Related Posts
How to Attract the Right Buyers: What Makes a Business More ValuableIn the dynamic world of mergers and acquisitions (M&A), selling your business is a complex process that requires strategic planning, valuation expertise, and an understanding of what potential buyers are looking for. Buyers and investors are driven by various motives, including growth acceleration, market expansion, and portfolio diversification. Successfully attracting the right buyers can significantly impact the sale price and the overall success of the transaction. But what exactly can make your business more valuable and appealing to prospective buyers? Let’s explore the key factors that may enhance your company's attractiveness in M&A and how you can position your business for maximum appeal.Why Multi-Party Sale Processes Are an Opportunity for BuyersTo many acquirers, the words “competitive process” still carry an undertone of friction. They suggest distraction, inflated expectations, unnecessary pressure, and the risk of being used as a price tension rather than a serious counterparty. Yet this interpretation often misses the deeper reality. For most business owners, particularly founders and long-tenured operators, a multi-party sale process is not an act of aggression; it is an act of responsibility – to themselves, to the business, and to the buyer.